MabVax Therapeutics Begins Patient Enrollment at Memorial Sloan Kettering Cancer Center for Trial of Radioimmunotherapy for Advanced Pancreatic, Colon and Lung Cancers.
M2 PHARMA-October 12, 2017-MabVax Therapeutics Begins Patient Enrollment at Memorial Sloan Kettering Cancer Center for Trial of Radioimmunotherapy for Advanced Pancreatic, Colon and Lung Cancers
(C)2017 M2 COMMUNICATIONS
- US-based cancer treatment developer MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) has initiated patient enrollment at a second site, Memorial Sloan Kettering Cancer Center, in a Phase 1 clinical trial evaluating a new radioimmunotherapy product for patients with locally advanced or metastatic adenocarcinoma of the pancreas or other CA19-9 positive malignancies including colon and lung cancers, the company said.
MVT-1075 (177Lu-CHX-A''-DTPA-HuMab-5B1) combines a potent radiotherapy with the tumor targeting specificity of the HuMab-5B1 antibody.
MVT-5873 is a fully human IgG1 monoclonal antibody that targets sialyl Lewis A, an epitope on CA19-9, that is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors.
CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer.
With collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, MabVax has treated 50 patients with either the therapeutic antibody designated as MVT-5873 or its PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and has demonstrated early safety and specificity for the target.
MabVax is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Beacon Health Options elects Michael Ramseier as EVP & market president.|
|Next Article:||Janssen Submits NDA to US FDA for Apalutamide for Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.|